MPM BioImpact’s Xenon Pharmaceuticals XENE Stock Holding History

MPM BioImpact’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-588,706	Closed	-$34.2M	–	45
2026 Q1	$34.2M	Buy	588,706 +103,086	+21%	+$4.75M	2.64%	12
2025 Q4	$21.8M	Sell	485,620 -17,778	-4%	-$747K	2.49%	16
2025 Q3	$20.2M	Buy	503,398 +180,000	+56%	+$6.34M	3.31%	11
2025 Q2	$10.1M	Buy	323,398 +20,000	+7%	+$652K	1.75%	25
2025 Q1	$10.2M	Buy	303,398 +106,186	+54%	+$4.03M	1.75%	26
2024 Q4	$7.73M	Buy	197,212 +31,412	+19%	+$1.3M	1.1%	36
2024 Q3	$6.53M	Buy	+165,800	New	+$6.69M	0.98%	29

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

MPM BioImpact's XENE Position: Q2 2026 in Review

MPM BioImpact sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 588,706 shares — an estimated $34.2M sold.

MPM BioImpact first reported a position in XENE in Q3 2024 and held it in 7 quarters. The position peaked at $34.2M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

MPM BioImpact reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
MPM BioImpact sold 588,706 Xenon Pharmaceuticals shares in Q2 2026, an estimated $34.2M.
MPM BioImpact first reported a position in Xenon Pharmaceuticals in Q3 2024 and held it in 7 quarters.
MPM BioImpact's Xenon Pharmaceuticals position peaked at $34.2M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.